Potent, selective inhibitor of TGF-βRI, ALK4 and ALK7
SB 431542 is a potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor/ALK5 (IC50 = 94 nM), and its relatives ALK4 and ALK7. Suppresses TGF-β-induced proliferation of human osteosarcoma cells. Replaces SOX2 in reprogramming of fibroblasts into iPSCs. Stimulates proliferation, differentiation and sheet formation of ESC-derived endothelial cells. Inhibits TGF-β-induced EMT, migration, invasion and VEGF secretion in several human cancer cell lines.
SB 431542 synthesized to cGMP guidelines also available.
For more information about how SB 431542 may be used, see our protocols: 3D Culture of Lung Alveolar Cells, Differentiation of Hematopoietic Progenitors from hPSCs, Generating Midbrain Dopaminergic Neurons from hPSCs, Generating Vascular Organoids, Accelerated Induction of Cortical Neurons from hiPSCs .
| Marque | Tocris |
|---|---|
| Réf. B-LABO | BL-RE-124357 |
| Réf. fabricant | 18795776 |
| Nom chimique ou matériau | SB 431542 |
| CAS | 301836-41-9 |
| Synonyme | 4-4-2h-1,3-benzodioxol-5-yl-5-pyridin-2-yl-1h-imidazol-2-yl benzamide |
| Quantité | 10 mg |
| Formule moléculaire | C22H16N4O3 |
| Poids de la formule | 384.39 |
